Buprenorphine and Gonadorelin: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Gonadorelin
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Both buprenorphine and gonadorelin can, in theory, affect your heart's electrical rhythm in a way called QT prolongation. When two medicines that each carry this small risk are used together, the concern is that the effect could add up. This is a theoretical concern, meaning it hasn't been clearly proven with these two specific drugs, but it's worth taking seriously.
The good news is your care team can manage this. They may check your heart rhythm, review other risk factors like low potassium or magnesium, and decide the safest plan for you. Please don't stop either medicine on your own. Just bring this up with your doctor or pharmacist.
Effect: Additive risk of QT interval prolongation with concomitant buprenorphine and gonadorelin.
- Mechanism: Additive QT prolongation (PD interaction); neither agent is metabolically dependent on the other, and neither is a prodrug relevant here.
- Direction: Increased combined risk of QTc prolongation and torsades de pointes.
- Evidence: Theoretical; magnitude with this specific pair is not established.
- Onset: Unspecified.
- Management: Avoid concomitant use where feasible. If co-prescribed, assess baseline and periodic ECG, correct electrolytes (K+, Mg2+), and weigh risk factors (bradycardia, CHF, congenital long-QT, digoxin therapy, recent AF conversion).
What happens
An increased risk of QT interval prolongation
Interaction Deep Dive
The simultaneous use of buprenorphine alongside agents capable of extending the QT interval should be avoided 342. It remains unknown what risk arises from pairing buprenorphine with other QT-prolonging medications. When prescribing buprenorphine to patients who present with risk factors, including hypokalemia, bradycardia, recent conversion from atrial fibrillation, congestive heart failure, digitalis therapy, baseline QT prolongation, subclinical long-QT syndrome, or severe hypomagnesemia, clinicians should take these observations into account during their decision-making 1.
Why it happens (mechanism)
Additive QT interval prolongation
How to manage this interaction
Here is how a care team typically handles this combination:
- Avoid when possible: If another option exists, your prescriber may choose it, since the combined QT risk isn't fully quantified.
- Closer monitoring: Your team may order an ECG and check blood electrolytes such as potassium and magnesium.
- Review risk factors: Tell your team if you have heart failure, a slow heart rate, a known long-QT problem, or take digoxin.
Keep taking both medicines exactly as prescribed unless told otherwise. Report any fainting, palpitations, or dizziness promptly, and raise this interaction with your pharmacist or doctor.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Buprenorphine and Gonadorelin together?
Combining buprenorphine and gonadorelin may add up to a higher risk of QT prolongation, so your care team may avoid the combination or monitor your heart rhythm and electrolytes. Keep taking both as prescribed and report any fainting or palpitations. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Gonadorelin interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Gonadorelin interaction managed?
Here is how a care team typically handles this combination: Avoid when possible: If another option exists, your prescriber may choose it, since the combined QT risk isn't fully quantified. Closer monitoring: Your team may order an ECG and check blood electrolytes such as potassium and magnesium. Review risk factors: Tell your team if you have heart failure, a slow heart rate, a known long-QT probl… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Buprenorphine or Gonadorelin need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (4)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: BUTRANS(R) transdermal system patch, buprenorphine transdermal system patch. Purdue Pharma L.P. (per FDA), Stamford, CT, 2016. DailyMed
- Product Information: BELBUCA(TM) buccal film, buprenorphine buccal film. Endo Pharmaceuticals Inc. (per FDA), Malvern, PA, 2016.
- Product Information: BUPRENEX(R) intravenous injection, intramuscular injection, buprenorphine HCl intravenous injection, intramuscular injection. Indivior Inc. (per DailyMed), Richmond, VA, 2016. DailyMed
Keep reading about Buprenorphine
Keep reading about Gonadorelin
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist